Novavax logged a -0.3% change during today's morning session, and is now trading at a price of $7.64 per share.
Novavax returned losses of -85.7% last year, with its stock price reaching a high of $76.77 and a low of $5.61. Over the same period, the stock underperformed the S&P 500 index by -86.0%. As of April 2023, the company's 50-day average price was $7.63. Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. Based in Gaithersburg, MD, the mid-cap Health Care company has 1,992 full time employees. Novavax has not offered a dividend during the last year.
The Business Is Unprofitable and Its Balance Sheet Is Highly Leveraged:
| 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| Revenue (MM) | $19 | $476 | $1,146 | $1,599 |
| Revenue Growth | n/a | 2448.48% | 141.02% | 39.49% |
| Gross Margins | n/a | n/a | n/a | 43.6% |
| Gross Margins Growth | n/a | n/a | n/a | n/a |
| Operating Margins | -694.4% | -87.6% | -147.1% | -40.3% |
| Operating Margins Growth | n/a | 87.38% | -67.92% | 72.6% |
| Net Margins | -711.04% | -87.94% | -152.12% | -41.15% |
| Net Margins Growth | n/a | 87.63% | -72.98% | 72.95% |
| Earnings Per Share | -$5.51 | -$7.27 | -$23.44 | -$8.54 |
| EPS Growth | n/a | -31.94% | -222.42% | 63.57% |
| Diluted Shares (MM) | 24 | 58 | 74 | 86 |
| Free Cash Flow (MM) | -$138 | -$97 | $265 | -$509 |
| FCF Growth | n/a | 29.84% | 373.21% | -291.71% |
| Capital Expenditures (MM) | -$2 | -$55 | -$57 | -$93 |
| LT Debt to Equity | -1.72 | 0.51 | -0.92 | -0.26 |
Novavax does not have a meaningful trailing P/E ratio since its earnings per share are negative. Its forward EPS guidance is negative too, at $-1.7. The average P/E ratio for the Health Care sector is 24.45.
Novavax Has an Average Rating of Hold:
The 5 analysts following Novavax have set target prices ranging from $10.0 to $110.0 per share, for an average of $41.8 with a hold rating. As of April 2023, the company is trading -81.7% away from its average target price, indicating that there is an analyst consensus of strong upside potential.
Novavax has an unusually large proportion of its shares sold short because 39.8% of the company's shares are sold short. Institutions own 61.5% of the company's shares, and the insider ownership rate stands at 0.44%, suggesting a small amount of insider investors. The largest shareholder is the Vanguard Group, Inc., whose 10% stake in the company is worth $67,617,372.
